Table 2 Comparison of high risk variables between chronic hepatitis C (CHC) and hepatocellular carcinoma (HCC) patients

Age

>57years

20(40)

30(60)

0.44 (0.20-0.99)

0.04

Male gender

30(60)

31(62)

1.09(0.49-2.43)

0.84

Obese (BMI >25)

22(44)

20(40)

1.18(0.53-2.61)

0.68

LFT

ALT (>37 IU/L)

46(92)

47(94)

0.73(0.16-3.46)

>0.99

AST (>40 IU/L)

37(74)

50(100)

1.35(1.15-1.59)

<0.001

T. Bil (> 1 mg/dL)

24(48)

50(100)

2.08(1.56-2.78)

<0.001

Albumin (>5.3 g/dL)

0

0

INR (> 1)

32(64)

50(100)

1.56(1.27-1.92)

<0.001

GGT (>50 IU/L)

30(60)

50(100)

1.67 (1.33-2.09)

<0.001

Biochemical tests

Fasting Glucose

(>110 mg/dL)

48(96)

42(84)

4.57(0.92-22.73)

0.09

Fasting Insulin (>6.IU/mL)

37(74)

42(84)

0.54 (0.20-1.45)

0.22

HbA1c (>7%)

24(48)

35(70)

0.40(0.17-0.90)

0.02

HOMA-IR (>4)

20(40)

26 (52)

1.63 (0.74-3.59)

0.23

Plt (>400 × 10⁹/L)

0

0

-

Cholesterol (>200 mg/dL)

17(34)

20(40)

1.29 (0.57-2.92)

0.63

TG (> 150 mg/dL)

48(96)

47(94)

1.53(0.24-9.59)

>0.99

Tumor marker

Serum AFP (>10 ng/mL)

30(12-57)

255(220-310)

26.00(6.68-101.20)

<0.001

HCV RNA (viral load) N(%)

Moderate (100-1000 × 10³) n = 56

21(42)

35(70)

-

<0.001

Stage of Fibrosis

III-V (n = 83)

34(68)

49(98)

23.06 (2.92-82.21)

<0.001